About Our Team

Kira’s experienced team includes established drug developers and protein engineers, world-renowned experts in complement biology and leaders from across the pharma and biotech industry. The team is augmented by well-respected academic collaborators at major US and European research institutions alongside an outstanding Scientific Advisory Board with international reputations in complement biology and immunology. This extensive team is working together tirelessly to pioneer a world free from complement disease.

With our headquarters in Cambridge, Massachusetts, and offices in Suzhou and Shanghai, China, and Australia, Kira Pharmaceuticals is committed to establishing a global footprint and advancing life-changing therapies to patients around the world.

Leadership

Frederick Beddingfield, MD, PhD
CEO
Helen Fu, MBA
VP and Head of Corporate Portfolio and Project Management
Richard Lee, MD
Chief Medical Officer
Teri Loxam
COO & CFO
Gonghua Pan, MBA PhD
Head of External Alliances and Special Projects, Co-Founder
Martin Rabe
Senior Vice President, Head of Global Regulatory Affairs
Wenru Song, MD, PhD
President & Head of R&D, Co-founder
Angela Yan
President of China and Asia Development and Operations

Scientific Advisory Board

Wen Chao Song, PhD
Kira Scientific Founder & Chair; UPenn
Paul Morgan, MB, PhD
Systems Immunity Research Institute – Cardiff University
Jörg Köhl, MD
Institute for Systemic Inflammation Research – Lübeck University
Garret A. FitzGerald, MD, FRS
The FitzGerald Lab – UPenn
Ronald Levy, MD
Stanford School of Medicine; Stanford Cancer Institute

Our Investors

Get in touch with us!

Get in touch to learn more about our LOGIC discovery platform and pipeline.